Proteasome activator enhances survival of Huntington's disease neuronal model cells

113Citations
Citations of this article
104Readers
Mendeley users who have this article in their library.

Abstract

In patients with Huntington's disease (HD), the proteolytic activity of the ubiquitin proteasome system (UPS) is reduced in the brain and other tissues. The pathological hallmark of HD is the intraneuronal nuclear protein aggregates of mutant huntingtin. We determined how to enhance UPS function and influence catalytic protein degradation and cell survival in HD. Proteasome activators involved in either the ubiquitinated or the non-ubiquitinated proteolysis were overexpressed in HD patients' skin fibroblasts or mutant huntingtin-expressing striatal neurons. Following compromise of the UPS, overexpression of the proteasome activator subunit PA28γ, but not subunit S5a, recovered proteasome function in the HD cells. PA28c also improved cell viability in mutant huntingtin-expressing striatal neurons exposed to pathological stressors, such as the excitotoxin quinolinic acid and the reversible proteasome inhibitor MG132. These results demonstrate the specific functional enhancements of the UPS that can provide neuroprotection in HD cells. © 2007 Seo et al.

Cite

CITATION STYLE

APA

Seo, H., Sonntag, K. C., Kim, W., Cattaneo, E., & Isacson, O. (2007). Proteasome activator enhances survival of Huntington’s disease neuronal model cells. PLoS ONE, 2(2). https://doi.org/10.1371/journal.pone.0000238

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free